Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men

Ilir Agalliu, Wendy J. Langeberg, Johanna W. Lampe, Claudia A. Salinas, Janet L. Stanford

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

BACKGROUND. The glutathione S-transferase (GST) enzymes detoxify several carcinogens. Genetic polymorphisms in GSTM1, T1, and P1 (Ile105Val) have been associated with prostate cancer, however, results have been inconsistent across studies. METHODS. Data from a population-based case-control study in King County, Washington, were used to further evaluate the relationships between these GST polymorphisms and prostate cancer. Incident cases (n = 590) were 40-64 years old, diagnosed from 1993 through 1996, and identified via the SEER cancer registry. Controls (n = 538) were identified via random digit dialing, and frequency age-matched to cases. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). RESULTS. Risk of prostate cancer was moderately increased among Caucasians with the GSTM1-null genotype (OR = 1.54; 95% CI 1.19-2.01). There were no associations for either GSTT1 or P1 (Ile105Val). The association between the GSTM1-null genotype and prostate cancer was not different according to cancer aggressiveness defined by stage at diagnosis and Gleason score. Among GSTM1-null Caucasians, the relative risk of prostate cancer increased linearly with increasing pack-years of smoking (P-value for trend = 0.007), with the highest ORs observed for smokers of >30 pack-years. CONCLUSIONS. Findings suggest that the GSTM1-null genotype defines a subgroup of men at higher risk of prostate cancer, particularly if they are heavy smokers.

Original languageEnglish (US)
Pages (from-to)146-156
Number of pages11
JournalProstate
Volume66
Issue number2
DOIs
StatePublished - Feb 1 2006
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Genotype
Glutathione Transferase
Odds Ratio
Confidence Intervals
Neoplasm Grading
Genetic Polymorphisms
Carcinogens
Registries
glutathione S-transferase T1
glutathione S-transferase M1
Case-Control Studies
Neoplasms
Logistic Models
Smoking
Enzymes
Population

Keywords

  • Gene-environment interactions
  • Genetic polymorphisms
  • Glutathione S-transferase
  • Population-attributable risk percent
  • Prostate cancer

ASJC Scopus subject areas

  • Urology

Cite this

Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. / Agalliu, Ilir; Langeberg, Wendy J.; Lampe, Johanna W.; Salinas, Claudia A.; Stanford, Janet L.

In: Prostate, Vol. 66, No. 2, 01.02.2006, p. 146-156.

Research output: Contribution to journalArticle

Agalliu, Ilir ; Langeberg, Wendy J. ; Lampe, Johanna W. ; Salinas, Claudia A. ; Stanford, Janet L. / Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men. In: Prostate. 2006 ; Vol. 66, No. 2. pp. 146-156.
@article{9796c040134743cf9dd2323acbe5cb93,
title = "Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men",
abstract = "BACKGROUND. The glutathione S-transferase (GST) enzymes detoxify several carcinogens. Genetic polymorphisms in GSTM1, T1, and P1 (Ile105Val) have been associated with prostate cancer, however, results have been inconsistent across studies. METHODS. Data from a population-based case-control study in King County, Washington, were used to further evaluate the relationships between these GST polymorphisms and prostate cancer. Incident cases (n = 590) were 40-64 years old, diagnosed from 1993 through 1996, and identified via the SEER cancer registry. Controls (n = 538) were identified via random digit dialing, and frequency age-matched to cases. Logistic regression was used to estimate odds ratios (OR) and 95{\%} confidence intervals (CI). RESULTS. Risk of prostate cancer was moderately increased among Caucasians with the GSTM1-null genotype (OR = 1.54; 95{\%} CI 1.19-2.01). There were no associations for either GSTT1 or P1 (Ile105Val). The association between the GSTM1-null genotype and prostate cancer was not different according to cancer aggressiveness defined by stage at diagnosis and Gleason score. Among GSTM1-null Caucasians, the relative risk of prostate cancer increased linearly with increasing pack-years of smoking (P-value for trend = 0.007), with the highest ORs observed for smokers of >30 pack-years. CONCLUSIONS. Findings suggest that the GSTM1-null genotype defines a subgroup of men at higher risk of prostate cancer, particularly if they are heavy smokers.",
keywords = "Gene-environment interactions, Genetic polymorphisms, Glutathione S-transferase, Population-attributable risk percent, Prostate cancer",
author = "Ilir Agalliu and Langeberg, {Wendy J.} and Lampe, {Johanna W.} and Salinas, {Claudia A.} and Stanford, {Janet L.}",
year = "2006",
month = "2",
day = "1",
doi = "10.1002/pros.20305",
language = "English (US)",
volume = "66",
pages = "146--156",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Glutathione S-transferase M1, T1, and P1 polymorphisms and prostate cancer risk in middle-aged men

AU - Agalliu, Ilir

AU - Langeberg, Wendy J.

AU - Lampe, Johanna W.

AU - Salinas, Claudia A.

AU - Stanford, Janet L.

PY - 2006/2/1

Y1 - 2006/2/1

N2 - BACKGROUND. The glutathione S-transferase (GST) enzymes detoxify several carcinogens. Genetic polymorphisms in GSTM1, T1, and P1 (Ile105Val) have been associated with prostate cancer, however, results have been inconsistent across studies. METHODS. Data from a population-based case-control study in King County, Washington, were used to further evaluate the relationships between these GST polymorphisms and prostate cancer. Incident cases (n = 590) were 40-64 years old, diagnosed from 1993 through 1996, and identified via the SEER cancer registry. Controls (n = 538) were identified via random digit dialing, and frequency age-matched to cases. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). RESULTS. Risk of prostate cancer was moderately increased among Caucasians with the GSTM1-null genotype (OR = 1.54; 95% CI 1.19-2.01). There were no associations for either GSTT1 or P1 (Ile105Val). The association between the GSTM1-null genotype and prostate cancer was not different according to cancer aggressiveness defined by stage at diagnosis and Gleason score. Among GSTM1-null Caucasians, the relative risk of prostate cancer increased linearly with increasing pack-years of smoking (P-value for trend = 0.007), with the highest ORs observed for smokers of >30 pack-years. CONCLUSIONS. Findings suggest that the GSTM1-null genotype defines a subgroup of men at higher risk of prostate cancer, particularly if they are heavy smokers.

AB - BACKGROUND. The glutathione S-transferase (GST) enzymes detoxify several carcinogens. Genetic polymorphisms in GSTM1, T1, and P1 (Ile105Val) have been associated with prostate cancer, however, results have been inconsistent across studies. METHODS. Data from a population-based case-control study in King County, Washington, were used to further evaluate the relationships between these GST polymorphisms and prostate cancer. Incident cases (n = 590) were 40-64 years old, diagnosed from 1993 through 1996, and identified via the SEER cancer registry. Controls (n = 538) were identified via random digit dialing, and frequency age-matched to cases. Logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CI). RESULTS. Risk of prostate cancer was moderately increased among Caucasians with the GSTM1-null genotype (OR = 1.54; 95% CI 1.19-2.01). There were no associations for either GSTT1 or P1 (Ile105Val). The association between the GSTM1-null genotype and prostate cancer was not different according to cancer aggressiveness defined by stage at diagnosis and Gleason score. Among GSTM1-null Caucasians, the relative risk of prostate cancer increased linearly with increasing pack-years of smoking (P-value for trend = 0.007), with the highest ORs observed for smokers of >30 pack-years. CONCLUSIONS. Findings suggest that the GSTM1-null genotype defines a subgroup of men at higher risk of prostate cancer, particularly if they are heavy smokers.

KW - Gene-environment interactions

KW - Genetic polymorphisms

KW - Glutathione S-transferase

KW - Population-attributable risk percent

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=31944435043&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31944435043&partnerID=8YFLogxK

U2 - 10.1002/pros.20305

DO - 10.1002/pros.20305

M3 - Article

C2 - 16173036

AN - SCOPUS:31944435043

VL - 66

SP - 146

EP - 156

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 2

ER -